Insulin Secretion Articles & Analysis
9 news found
Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options. ...
Creative Enzymes, a leading provider of high-quality enzymes and biochemicals, is proud to announce the addition of Semaglutide to its comprehensive product portfolio. This novel glucagon-like peptide-1 (GLP-1) receptor agonist has generated significant excitement within the pharmaceutical and life sciences industries due to its remarkable efficacy in managing type 2 diabetes. Semaglutide ...
Advancements in drug delivery technology have paved the way for more efficient and targeted treatment options. Among these innovations is the development of coated microneedle preparation technology, which has shown promising results in delivering novel drugs to patients. CD formulation involves coated microneedles with specific drug compounds, allowing for controlled and sustained drug delivery. ...
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...
ByBayer AG
BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. The absolute lack of insulin, due to destruction of the ...
The first patient has now received its first intralymphatic injection of Diamyd® in the precision medicine Phase III trial DIAGNODE-3. The trial will include approximately 330 patients aged 12 to 29 years newly diagnosed with Type 1 Diabetes who carry the genetically defined haplotype HLA DR3-DQ2. “The fact that the first patient is now enrolled in DIAGNODE-3 is a major milestone for ...
Ness Ziona, Israel, July, 2021 --- Cell therapy company Kadimastem Ltd (TASE: KDST) has received its patent approval from the Japanese Patent Office for IsletRx, the company’s innovative treatment for diabetes. IsletRx comprises an expanded population of clinical grade pancreatic islet-like cluster (ILCs) cells, derived from human stem cells, that have the ability to secrete insulin when ...
The Start-up Nation has made several ground breaking discoveries in the fields of technology, science, and innovation during the past decade.The first artificial pancreas – A potential cure for diabetes? In a possible future cure for diabetes, researchers at Betalin Therapeutics have engineered the first artificial pancreas. It can be inserted underneath the skin, without anesthesia and ...
Never mind better insulin shots or cell implants for diabetics: Betalin Therapeutics has a unique approach. A young Israeli company that has cured type-1 diabetes in mice and hopes to do the same for humans one day has won the MIXiii Biomed 2017 pharma startup competition, beating dozens of other firms. Just how cured were these mice, exactly? “They were cured of advanced stages of severe ...